阿那白滞素预防大B细胞淋巴瘤患者接受阿基仑赛治疗后突破性毒性的单细胞动态研究
本研究旨在评估每日一次阿那白滞素预防接受阿基仑赛治疗的大细胞淋巴瘤患者发生需住院的细胞因子释放综合征(CRS)或神经毒性(NT)(≥2级),以促进门诊治疗,并前瞻性整合单细胞RNA测序探索突破性毒性的免疫信号。研究发现每日一次阿那白滞素不足以预防大多数患者发生需住院的毒性,突破性CRS或NT患者中干扰素γ(IFN-γ)通路及配体-受体活性显著富集,CD14+单核细胞中IFN-γ和CXCL10水平升高,外周血IFN-γ及其他细胞因子亦升高;输注的CAR-T产品中IL-4和IL-10抗炎通路与≥2级毒性呈负相关,与阿那白滞素治疗无关。
要点
- 每日一次阿那白滞素预防不足以防止大多数患者发生需住院的CRS/NT(≥2级)。
- 突破性CRS或NT患者中IFN-γ通路和配体-受体活性显著富集,CD14+单核细胞中IFN-γ和CXCL10升高。
- 输注CAR-T产品中IL-4和IL-10抗炎通路与≥2级毒性负相关,与阿那白滞素无关。
核心结论
- 每日一次预防性阿那白滞素不足以预防大多数接受阿基仑赛治疗的大细胞淋巴瘤患者发生需住院的毒性。
- IFN-γ是CAR-T相关毒性的潜在关键机制,不被阿那白滞素抑制,但可能可通过其他途径靶向。
研究设计与样本
- 前瞻性研究,在接受阿基仑赛治疗的大细胞淋巴瘤患者中评估每日一次预防性阿那白滞素(IL-1受体拮抗剂)预防需住院的CRS/NT(≥2级),并前瞻性整合单细胞RNA测序。
- 试验注册号:NCT04150913。
主要发现
- 每日一次预防性阿那白滞素不足以预防大多数患者发生需住院的毒性。
- 发生突破性CRS或NT的患者中,IFN-γ通路和配体-受体活性显著富集,CD14+单核细胞中IFN-γ和CXCL10水平升高。
- 突破性CRS或NT患者外周血中IFN-γ及其他细胞因子升高。
- 输注的CAR-T产品中IL-4和IL-10抗炎通路与≥2级毒性呈负相关,与阿那白滞素治疗无关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chimeric antigen receptor (CAR) T-cell (CAR-T) therapy is limited by cytokine release syndrome (CRS) and neurotoxicity (NT). We sought to use once-daily prophylactic anakinra, an interleukin-1 (IL-1) receptor antagonist, to prevent CRS/NT that would require hospitalization (grade ≥2) in patients receiving axicabtagene ciloleucel for large-cell lymphoma, with the goal of facilitating outpatient therapy and management. Our study, in line with others, demonstrates that once-daily prophylactic anakinra is insufficient to prevent the development of toxicities that would require hospitalization in most patients. As part of the initial study design, we prospectively incorporated single-cell RNA sequencing to gain insight into the molecular immune signaling associated with breakthrough CRS and NT despite anakinra prophylaxis. In patients who developed breakthrough CRS or NT, we found that interferon gamma (IFN-γ) pathways and ligand-receptor activities were significantly enriched, as were cytokine levels of IFN-γ and CXCL10 in CD14+ monocytes. This correlated with increased IFN-γ and other cytokines in the peripheral blood. In infused CAR-T products, IL-4 and IL-10 anti-inflammatory pathways were negatively associated with grade ≥2 toxicities, regardless of anakinra treatment. These data identify IFN-γ as a potential key mechanism in CAR-T-associated toxicities, which is not inhibited by anakinra but may be otherwise targetable. This trial was registered at www.ClinicalTrials.gov as #NCT04150913.
引用
- Frigault MJ, Yao N, Berger TR, et al. Single-cell dynamics of breakthrough toxicities after anakinra prophylaxis for axicabtagene ciloleucel in lymphoma. Blood Adv. 2025. PMID: 39928957. doi:10.1182/bloodadvances.2024015161
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。